Oral Aleniglipron Reduced Weight at 36 Weeks - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

  • 1

    Aleniglipron reduced body weight by 9% to 12% at 36 weeks in adults with obesity or overweight, compared to 1% with placebo.

  • 2

    The ACCESS trial involved 230 patients, aged 18 to 79 years, with a mean BMI of 39.5 kg/m² and a mean weight of 114.8 kg.

  • 3

    Gastrointestinal adverse events were common, occurring in 79% to 89% of aleniglipron-treated patients, with nausea being the most frequent.

  • 4

    At week 56, mean weight loss was 13.3%, 16.2%, and 15.3% for patients initially assigned to 45 mg, 90 mg, and 120 mg, respectively.

  • 5

    The study had limitations, including a predominantly White population and lower female participation compared to other obesity trials.

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Depression, anxiety symptoms may be common in T1D

National survey data show a greater mental health symptom burden among adults with type 1 diabetes vs. those with type 2 diabetes or no diabetes.

Medical Oddities: Your physiology may know when you're alone

The body gets weird this week with company, cavities, phantom smells, and black tea.

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.